Huang Ying, Lu Wen, Lu Hongyun
Department of Endocrinology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated With Jinan University, No.79 Kangning Road Zhuhai, Guangdong, 519000, China.
Diabetol Metab Syndr. 2022 Mar 29;14(1):47. doi: 10.1186/s13098-022-00815-y.
To investigate the clinical efficacy and safety of dapagliflozin in the treatment of diabetic nephropathy (DN).
A total of 120 DN patients admitted to our hospital from June 2017 to March 2020 were divided into control and experimental groups, with 60 cases in each group. The control group received valsartan, and the experimental group received dapagliflozin for 3 months. Body mass index (BMI), hemoglobin A1c (HbA1c), serum creatinine (sCr), uric acid (UA), urine microalbumin (uMA), urine creatinine (uCr), and bilateral kidney function were compared before and after treatment, and adverse reactions in both groups were observed. Serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were also evaluated.
After treatment, except for BMI in the control group, all indexes in both groups were significantly improved. The BMI, HbA1c, sCr, UA, and uMA/uCr ratios of the experimental group were lower than those of the control group. Serum albumin (sAlb) levels were increased in both groups, and the experimental group showed a significant difference compared with the control group. Estimated glomerular filtration rate (eGFR) levels were increased in both groups, and the experimental group was higher than the control group, with no significant differences. Serum IL-6 and TNF-α levels in both groups were lower, and the experimental group was significantly lower than the control group. No serious adverse reactions were observed in either group.
The efficacy of dapagliflozin was demonstrated by its ability to improve diabetes, prevent nephropathy exacerbation, and reduce symptomatic reactions. The low rate of adverse reactions makes dapagliflozin a very safe medication.
探讨达格列净治疗糖尿病肾病（DN）的临床疗效及安全性。
选取2017年6月至2020年3月我院收治的120例DN患者，分为对照组和试验组，每组60例。对照组给予缬沙坦，试验组给予达格列净治疗3个月。比较两组治疗前后的体重指数（BMI）、糖化血红蛋白（HbA1c）、血清肌酐（sCr）、尿酸（UA）、尿微量白蛋白（uMA）、尿肌酐（uCr）及双侧肾功能，并观察两组不良反应。同时评估血清白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）水平。
治疗后，除对照组BMI外，两组各项指标均显著改善。试验组的BMI、HbA1c、sCr、UA及uMA/uCr比值均低于对照组。两组血清白蛋白（sAlb）水平均升高，试验组与对照组相比差异有统计学意义。两组估算肾小球滤过率（eGFR）水平均升高，试验组高于对照组，但差异无统计学意义。两组血清IL-6和TNF-α水平均降低，试验组显著低于对照组。两组均未观察到严重不良反应。
达格列净可改善糖尿病、预防肾病加重并减轻症状反应，证实了其疗效。不良反应发生率低，表明达格列净是一种非常安全的药物。
